TriSalus Life Sciences In... (TLSI)
NASDAQ: TLSI
· Real-Time Price · USD
5.32
0.25 (4.93%)
At close: Jun 27, 2025, 3:59 PM
5.32
0.00%
After-hours: Jun 27, 2025, 05:50 PM EDT
Company Description
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors.
The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers.
The company is based in Westminster, Colorado.
TriSalus Life Sciences Inc.
| Country | United States |
| IPO Date | Feb 8, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Mary T. Szela B.S.N., |
Contact Details
Address: 6272 West 91st Avenue Westminster, Colorado United States | |
| Website | https://trisaluslifesci.com |
Stock Details
| Ticker Symbol | TLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826667 |
| CUSIP Number | 89680M101 |
| ISIN Number | US89680M1018 |
| Employer ID | 85-3009869 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Mary T. Szela B.S.N., M.B.A. | Chief Executive Officer, President & Director |
| James E. Young | Chief Financial Officer, Secretary & Treasurer |
| Dr. Bryan F. Cox Ph.D. | Chief of Research |
| Dr. Richard B. Marshak M.B.A., MBA, VMD | Chief Commercial Officer |
| Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Jodi Devlin | Chief of Clinical Strategy & Operations |
| Lori Ann Santamaria | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | 8-K | Current Report |
| Jun 23, 2025 | S-4 | Filing |
| Jun 23, 2025 | SC TO-I | Filing |
| Jun 16, 2025 | 8-K | Current Report |
| May 30, 2025 | S-3 | Filing |
| May 30, 2025 | 8-K | Current Report |
| May 30, 2025 | 10-K/A | [Amend] Annual Report |
| May 21, 2025 | 4 | Filing |
| May 21, 2025 | 4 | Filing |
| May 21, 2025 | 4 | Filing |